Plerixafor injection
Products billed under this code include Plerixafor.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Plerixafor.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Plerixafor | Sanofi-Aventis U.S. LLC | 00024-5862-01 | 24 | $1,030.632 |
| Plerixafor | Teva Pharmaceuticals USA, Inc. | 00480-4320-01 | 24 | $1,030.632 |
| Plerixafor | Sagent Pharmaceuticals | 25021-0416-01 | 24 | $1,030.632 |
| Plerixafor | Dr. Reddy's Laboratories Inc. | 43598-0308-23 | 24 | $1,030.632 |
| Plerixafor | Eugia US LLC | 55150-0356-01 | 24 | $1,030.632 |
| Plerixafor | FreseniUS Kabi USA, LLC | 65219-0284-12 | 24 | $1,030.632 |
| Plerixafor | Amneal Pharmaceuticals, LLC | 70121-1694-02 | 24 | $1,030.632 |
| Plerixafor | Zydus Pharmaceuticals (USA) Inc. | 70710-1208-01 | 24 | $1,030.632 |
| Plerixafor | Meitheal Pharmaceuticals Inc. | 71288-0155-01 | 24 | $1,030.632 |
| Plerixafor | Novadoz Pharmaceuticals LLC | 72205-0249-01 | 24 | $1,030.632 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $42.943 | +$14.454 | 1 MG | Plerixafor injection | v1, posted September 17, 2026 |
| 3Q26 | $28.489 | −$4.254 | 1 MG | Plerixafor injection | v1, posted September 15, 2026 |
| 2Q26 | $32.743 | +$2.08 | 1 MG | Plerixafor injection | v1, posted September 15, 2026 |
| 1Q26 | $30.663 | +$5.332 | 1 MG | Plerixafor injection | v1, posted September 15, 2026 |
| 4Q25 | $25.331 | −$94.138 | 1 MG | Plerixafor injection | v1, posted September 8, 2026 |
| 3Q25 | $119.469 | +$94.493 | 1 MG | Plerixafor injection | v1, posted March 10, 2026 |
| 2Q25 | $24.976 | −$12.102 | 1 MG | Plerixafor injection | v1, posted March 10, 2026 |
| 1Q25 | $37.078 | −$13.393 | 1 MG | Plerixafor injection | v1, posted December 19, 2025 |
| 4Q24 | $50.471 | −$76.942 | 1 MG | Plerixafor injection | v1, posted June 11, 2025 |
| 3Q24 | $127.413 | +$3.834 | 1 MG | Plerixafor injection | v1, posted June 11, 2025 |
| 2Q24 | $123.579 | −$49.304 | 1 MG | Plerixafor injection | v1, posted March 11, 2025 |
| 1Q24 | $172.883 | −$256.17 | 1 MG | Plerixafor injection | v1, posted December 19, 2024 |
| 4Q23 | $429.053 | −$0.31 | 1 MG | Plerixafor injection | v1, posted October 10, 2024 |
| 3Q23 | $429.363 | +$27.788 | 1 MG | Plerixafor injection | v1, posted June 5, 2024 |
| 2Q23 | $401.575 | −$0.347 | 1 MG | Plerixafor injection | v1, posted February 23, 2024 |
| 1Q23 | $401.922 | −$0.678 | 1 MG | Plerixafor injection | v1, posted December 6, 2023 |
| 4Q22 | $402.60 | +$0.062 | 1 MG | Plerixafor injection | v1, posted June 22, 2023 |
| 3Q22 | $402.538 | +$19.89 | 1 MG | Plerixafor injection | v1, posted June 9, 2023 |
| 2Q22 | $382.648 | −$0.132 | 1 MG | Plerixafor injection | v1, posted December 14, 2022 |
| 1Q22 | $382.78 | −$0.072 | 1 MG | Plerixafor injection | v1, posted June 8, 2022 |
| 4Q21 | $382.852 | +$0.212 | 1 MG | Plerixafor injection | v1, posted June 2, 2022 |
| 3Q21 | $382.64 | +$17.481 | 1 MG | Plerixafor injection | v1, posted June 2, 2022 |
| 2Q21 | $365.159 | +$0.144 | 1 MG | Plerixafor injection | v1, posted March 1, 2022 |
| 1Q21 | $365.015 | – | 1 MG | Plerixafor injection | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.